Vtesse Company
Vtesse's lead compound, VTS-270, has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease.
Technology:
Others
Industry:
PharmTech
Headquarters:
Gaithersburg, Maryland, United States
Founded Date:
2014
Employees Number:
11-50
Funding Status:
M&A
Estimated Revenue:
$1M to $10M
Register and Claim Ownership